Videos

Panelists discuss how practice improvements and patient resources can be implemented to empower both health care providers and patients who have ALK-positive disease.

Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.

Panelists discuss how patient education strategies support long-term treatment success, adherence, and shared decision-making.

Panelists discuss how they monitor and educate patients on ALK inhibitor side adverse effects while equipping nursing staff to manage toxicities proactively.

Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.

The role of nurses and APPs is crucial to ensuring patients with cancer can receive newer therapies, shares David A. Braun, MD, PhD.

Nurse practitioner Beth Faiman shares strategies to reduce infection risk in patients receiving bispecific antibodies for multiple myeloma.

Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, outlines best practices for safely transitioning patients with multiple myeloma on bispecific antibodies to community care.

Panelists discuss how patient-specific factors, including brain metastases and drug tolerability, influence front-line ALK inhibitor selection.

Panelists discuss how they manage adverse events associated with ALK inhibitors, comparing safety profiles and addressing unique patient concerns.

Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.

Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.

Nurse practitioner Beth Faiman outlines nursing strategies to monitor, assess, and manage toxicities associated with talquetamab in multiple myeloma.

Panelists discuss how they guide first-line ALK inhibitor selection based on efficacy, tolerability, clinical data, and patient-specific considerations.

Panelists discuss how they prepare patients for ALK inhibitor therapy following a confirmed ALK-positive result.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

David A. Braun, MD, PhD, explained that personalized cancer vaccines can be associated with toxicities typical of both vaccines and immunotherapies.

Panelists discuss how strategic nursing coordination and effective communication support timely and comprehensive biomarker testing for newly diagnosed NSCLC patients.

Panelists discuss how evolving clinical advances and biomarker-driven therapies have transformed treatment practices and outcomes for patients with ALK+ NSCLC.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.

Ronald Bleday, MD, explained that a model to reduce opioid use in patients after colorectal surgery relies on nurses familiar with the relevant surgeries.

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain fog and weight gain while maintaining disease control, emphasizing the importance of multidisciplinary team support, including palliative care from diagnosis.

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient quality of life, while emphasizing that temporary treatment holds due to adverse effects are manageable, and ongoing research is vital to address unmet needs and advance multiple myeloma care.